Published in N Engl J Med on August 27, 2008
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) | NCT00338260
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | NCT00153062
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care (2011) 2.23
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med (2009) 1.05
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update. Can J Cardiol (2009) 1.03
Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation (2010) 1.01
2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol (2010) 0.99
Newer is not always better: all antihypertensive medications do not equally reduce cardiovascular risk. J Gen Intern Med (2012) 0.94
Small vessel cerebrovascular disease: the past, present, and future. Stroke Res Treat (2012) 0.92
Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2. Antioxid Redox Signal (2012) 0.91
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol (2009) 0.91
Blood pressure: the lower, the better: the con side. Diabetes Care (2011) 0.91
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation. Stroke (2013) 0.89
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Antihypertensive drugs and glucose metabolism. World J Cardiol (2014) 0.87
Impaired cerebral autoregulation is associated with brain atrophy and worse functional status in chronic ischemic stroke. PLoS One (2012) 0.86
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci (2013) 0.86
Angiotensin-converting enzyme inhibitors will not help in improving stroke outcome if given immediately after stroke. Ann Indian Acad Neurol (2010) 0.86
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One (2010) 0.85
Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2016) 0.85
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetol (2012) 0.85
ACE2 and diabetes: ACE of ACEs? Diabetes (2010) 0.84
Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag (2009) 0.84
Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care (2011) 0.84
Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther (2010) 0.84
Stroke prevention--insights from incoherence. N Engl J Med (2008) 0.82
The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: Its Essentials and Key Points. Pulse (Basel) (2015) 0.82
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiol (2013) 0.82
PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro (2013) 0.82
New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag (2010) 0.82
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag (2012) 0.81
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke (2012) 0.81
Lowering of blood pressure for recurrent stroke prevention. Stroke (2014) 0.81
Pre-hypertension: how low to go and do drugs have a role? Br J Clin Pharmacol (2012) 0.81
The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]. Implement Sci (2010) 0.80
Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag (2011) 0.80
The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf (2015) 0.80
Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials. Medicine (Baltimore) (2016) 0.79
Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab (2012) 0.79
Blood Pressure Management After Intracerebral Hemorrhage. Curr Treat Options Neurol (2015) 0.79
Clinical neuroprotective drugs for treatment and prevention of stroke. Int J Mol Sci (2012) 0.79
The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc Health Risk Manag (2009) 0.79
Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.79
Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011? J Zhejiang Univ Sci B (2011) 0.78
Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril. Vasc Health Risk Manag (2014) 0.78
Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. Transl Res (2014) 0.78
RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract (2013) 0.78
Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vasc Health Risk Manag (2011) 0.77
The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report. Vasc Health Risk Manag (2013) 0.77
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade. Clin J Am Soc Nephrol (2016) 0.77
Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy. Exp Ther Med (2012) 0.77
PPARs: Protectors or Opponents of Myocardial Function? PPAR Res (2015) 0.77
Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke (2011) 0.77
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Blood pressure and diabetic nephropathy. Diabetes Care (2010) 0.76
Understanding and treating hypertension in diabetic populations. Cardiovasc Diagn Ther (2015) 0.76
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag (2011) 0.76
An overview of candesartan in clinical practice. Expert Rev Cardiovasc Ther (2011) 0.76
Telmisartan and cardioprotection. Vasc Health Risk Manag (2011) 0.76
Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008. Clin Res Cardiol (2008) 0.75
A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vasc Health Risk Manag (2009) 0.75
Heart failure. BMJ Clin Evid (2011) 0.75
Telmisartan for prevention of cardiovascular events. N Engl J Med (2009) 0.75
Telmisartan for prevention of cardiovascular events. N Engl J Med (2009) 0.75
Use of renin-angiotensin system blockade in patients with renal artery stenosis. Clin J Am Soc Nephrol (2014) 0.75
Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clin Hypertens (2017) 0.75
Impact of a better persistence with antihypertensive agents on ischemic stroke outcomes for secondary prevention. PLoS One (2013) 0.75
Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart (2015) 0.75
Impact of telmisartan in modifying vascular risk. Integr Blood Press Control (2010) 0.75
ACP Journal Club. Telmisartan did not prevent recurrent stroke or major cardiovascular events. Ann Intern Med (2009) 0.75
Update of secondary stroke prevention. Nephrol Dial Transplant (2009) 0.75
Is telmisartan effective for stroke prevention? Am Fam Physician (2009) 0.75
Perindopril for improving cardiovascular events. Vasc Health Risk Manag (2014) 0.75
Elevated blood pressure in the acute phase of stroke and the role of Angiotensin receptor blockers. Int J Hypertens (2013) 0.75
Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J Stroke (2015) 0.75
Stage A: can heart failure be prevented? Curr Cardiol Rev (2015) 0.75
Joint Commission primary stroke center certification does not affect proband enrollment: the siblings with ischemic stroke study. J Stroke Cerebrovasc Dis (2009) 0.75
Telmisartan for prevention of cardiovascular events. N Engl J Med (2009) 0.75
Cardio classics revisited--focus on the role of candesartan. Vasc Health Risk Manag (2010) 0.75
Telmisartan did not prevent recurrent stroke or major cardiovascular events. Evid Based Med (2009) 0.75
Recent advances in the management of hypertension. F1000 Med Rep (2010) 0.75
Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. Clin Interv Aging (2015) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 17.97
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 12.67
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet (2007) 6.80
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke (2003) 4.63
Blood pressure and clinical outcomes in the International Stroke Trial. Stroke (2002) 3.94
Ramipril and the development of diabetes. JAMA (2001) 3.38
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J (2006) 1.24
Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke. Stroke (2005) 1.22
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 12.06
Universal definition of myocardial infarction. Circulation (2007) 11.69
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19
Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 7.89
Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell (2008) 7.68
1,026 experimental treatments in acute stroke. Ann Neurol (2006) 7.23
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36
Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 5.44
NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med (2012) 5.11